Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of CX601 (allogeneic expanded adipose-derived stem cells) for perianal fistulising Crohn's disease
2011-006064-43Phase 3Completed
- Sponsor
- TiGenix
- Start
- Feb 2012
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease and anal fistula comparing CX601 with Placebo (2 arms). Primary endpoint: Remission of perianal fistulising Crohn's disease at week 24. Started Feb 2012; status: completed.
02
Drugs
darvadstrocel
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on 2011-006064-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006064-43.